Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
21
ORKA Quote, Financials, Valuation and Earnings
Last price:
$27.80
Seasonality move
:
-8.05%
Day range:
$26.46 - $28.16
52-week range:
$5.49 - $32.64
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.64x
Volume:
334.1K
Avg. volume:
608.7K
1-year change:
46.55%
Market cap:
$1.3B
Revenue:
--
EPS (TTM):
-$2.42
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ORKA
Oruka Therapeutics, Inc.
|
-- | -$0.62 | -- | -1.78% | $52.17 |
|
CDT
CDT Equity, Inc.
|
-- | -- | -- | -- | -- |
|
LENZ
LENZ Therapeutics, Inc.
|
$1.5M | -$0.96 | -7.14% | -109.39% | $52.67 |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
-- | -$0.68 | -100% | -499.94% | $47.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ORKA
Oruka Therapeutics, Inc.
|
$26.40 | $52.17 | $1.3B | -- | $19.36 | 0% | -- |
|
CDT
CDT Equity, Inc.
|
$1.51 | -- | $2.5M | -- | $0.00 | 0% | -- |
|
LENZ
LENZ Therapeutics, Inc.
|
$15.24 | $52.67 | $476.9M | -- | $1.03 | 0% | 24.31x |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MAZE
Maze Therapeutics, Inc.
|
$38.95 | $47.33 | $1.9B | -- | $0.00 | 0% | 501.13x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ORKA
Oruka Therapeutics, Inc.
|
0.39% | 1.530 | 0.2% | 16.65x |
|
CDT
CDT Equity, Inc.
|
30.47% | -0.944 | 27% | 1.13x |
|
LENZ
LENZ Therapeutics, Inc.
|
0.49% | -0.162 | 0.07% | 12.39x |
|
LIMN
Liminatus Pharma
|
-- | 0.000 | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
5.99% | 0.000 | 1.94% | 17.36x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ORKA
Oruka Therapeutics, Inc.
|
-$20K | -$34.1M | -25.67% | -25.76% | -- | -$21.7M |
|
CDT
CDT Equity, Inc.
|
-$885K | -$7M | -898.82% | -- | -- | -$4.4M |
|
LENZ
LENZ Therapeutics, Inc.
|
$12.4M | -$18.9M | -28.93% | -29.1% | -151.1% | -$9M |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
-$571K | -$33M | -30.65% | -35.16% | -- | -$24.7M |
Oruka Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ORKA or CDT?
CDT Equity, Inc. has a net margin of -- compared to Oruka Therapeutics, Inc.'s net margin of --. Oruka Therapeutics, Inc.'s return on equity of -25.76% beat CDT Equity, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ORKAOruka Therapeutics, Inc.-- -$0.69 $488.7M CDTCDT Equity, Inc.-- -$13.16 $6.2M -
What do Analysts Say About ORKA or CDT?
Oruka Therapeutics, Inc. has a consensus price target of $52.17, signalling upside risk potential of 97.6%. On the other hand CDT Equity, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Oruka Therapeutics, Inc. has higher upside potential than CDT Equity, Inc., analysts believe Oruka Therapeutics, Inc. is more attractive than CDT Equity, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORKAOruka Therapeutics, Inc.11 0 0 CDTCDT Equity, Inc.0 0 0 -
Is ORKA or CDT More Risky?
Oruka Therapeutics, Inc. has a beta of -0.394, which suggesting that the stock is 139.44% less volatile than S&P 500. In comparison CDT Equity, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ORKA or CDT?
Oruka Therapeutics, Inc. has a quarterly dividend of $19.36 per share corresponding to a yield of 0%. CDT Equity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oruka Therapeutics, Inc. pays -- of its earnings as a dividend. CDT Equity, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORKA or CDT?
Oruka Therapeutics, Inc. quarterly revenues are --, which are smaller than CDT Equity, Inc. quarterly revenues of --. Oruka Therapeutics, Inc.'s net income of -$30.3M is lower than CDT Equity, Inc.'s net income of -$7.1M. Notably, Oruka Therapeutics, Inc.'s price-to-earnings ratio is -- while CDT Equity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oruka Therapeutics, Inc. is -- versus -- for CDT Equity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORKAOruka Therapeutics, Inc.-- -- -- -$30.3M CDTCDT Equity, Inc.-- -- -- -$7.1M
-
Which has Higher Returns ORKA or LENZ?
LENZ Therapeutics, Inc. has a net margin of -- compared to Oruka Therapeutics, Inc.'s net margin of -133.6%. Oruka Therapeutics, Inc.'s return on equity of -25.76% beat LENZ Therapeutics, Inc.'s return on equity of -29.1%.
Company Gross Margin Earnings Per Share Invested Capital ORKAOruka Therapeutics, Inc.-- -$0.69 $488.7M LENZLENZ Therapeutics, Inc.99% -$0.59 $194.9M -
What do Analysts Say About ORKA or LENZ?
Oruka Therapeutics, Inc. has a consensus price target of $52.17, signalling upside risk potential of 97.6%. On the other hand LENZ Therapeutics, Inc. has an analysts' consensus of $52.67 which suggests that it could grow by 245.58%. Given that LENZ Therapeutics, Inc. has higher upside potential than Oruka Therapeutics, Inc., analysts believe LENZ Therapeutics, Inc. is more attractive than Oruka Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORKAOruka Therapeutics, Inc.11 0 0 LENZLENZ Therapeutics, Inc.5 0 0 -
Is ORKA or LENZ More Risky?
Oruka Therapeutics, Inc. has a beta of -0.394, which suggesting that the stock is 139.44% less volatile than S&P 500. In comparison LENZ Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ORKA or LENZ?
Oruka Therapeutics, Inc. has a quarterly dividend of $19.36 per share corresponding to a yield of 0%. LENZ Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Oruka Therapeutics, Inc. pays -- of its earnings as a dividend. LENZ Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORKA or LENZ?
Oruka Therapeutics, Inc. quarterly revenues are --, which are smaller than LENZ Therapeutics, Inc. quarterly revenues of $12.5M. Oruka Therapeutics, Inc.'s net income of -$30.3M is lower than LENZ Therapeutics, Inc.'s net income of -$16.7M. Notably, Oruka Therapeutics, Inc.'s price-to-earnings ratio is -- while LENZ Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oruka Therapeutics, Inc. is -- versus 24.31x for LENZ Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORKAOruka Therapeutics, Inc.-- -- -- -$30.3M LENZLENZ Therapeutics, Inc.24.31x -- $12.5M -$16.7M
-
Which has Higher Returns ORKA or LIMN?
Liminatus Pharma has a net margin of -- compared to Oruka Therapeutics, Inc.'s net margin of --. Oruka Therapeutics, Inc.'s return on equity of -25.76% beat Liminatus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ORKAOruka Therapeutics, Inc.-- -$0.69 $488.7M LIMNLiminatus Pharma-- -- -- -
What do Analysts Say About ORKA or LIMN?
Oruka Therapeutics, Inc. has a consensus price target of $52.17, signalling upside risk potential of 97.6%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Oruka Therapeutics, Inc. has higher upside potential than Liminatus Pharma, analysts believe Oruka Therapeutics, Inc. is more attractive than Liminatus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings ORKAOruka Therapeutics, Inc.11 0 0 LIMNLiminatus Pharma0 0 0 -
Is ORKA or LIMN More Risky?
Oruka Therapeutics, Inc. has a beta of -0.394, which suggesting that the stock is 139.44% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ORKA or LIMN?
Oruka Therapeutics, Inc. has a quarterly dividend of $19.36 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oruka Therapeutics, Inc. pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORKA or LIMN?
Oruka Therapeutics, Inc. quarterly revenues are --, which are larger than Liminatus Pharma quarterly revenues of --. Oruka Therapeutics, Inc.'s net income of -$30.3M is higher than Liminatus Pharma's net income of --. Notably, Oruka Therapeutics, Inc.'s price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oruka Therapeutics, Inc. is -- versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORKAOruka Therapeutics, Inc.-- -- -- -$30.3M LIMNLiminatus Pharma-- -- -- --
-
Which has Higher Returns ORKA or MAZE?
Maze Therapeutics, Inc. has a net margin of -- compared to Oruka Therapeutics, Inc.'s net margin of --. Oruka Therapeutics, Inc.'s return on equity of -25.76% beat Maze Therapeutics, Inc.'s return on equity of -35.16%.
Company Gross Margin Earnings Per Share Invested Capital ORKAOruka Therapeutics, Inc.-- -$0.69 $488.7M MAZEMaze Therapeutics, Inc.-- -$0.63 $403.6M -
What do Analysts Say About ORKA or MAZE?
Oruka Therapeutics, Inc. has a consensus price target of $52.17, signalling upside risk potential of 97.6%. On the other hand Maze Therapeutics, Inc. has an analysts' consensus of $47.33 which suggests that it could grow by 21.52%. Given that Oruka Therapeutics, Inc. has higher upside potential than Maze Therapeutics, Inc., analysts believe Oruka Therapeutics, Inc. is more attractive than Maze Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORKAOruka Therapeutics, Inc.11 0 0 MAZEMaze Therapeutics, Inc.9 0 0 -
Is ORKA or MAZE More Risky?
Oruka Therapeutics, Inc. has a beta of -0.394, which suggesting that the stock is 139.44% less volatile than S&P 500. In comparison Maze Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ORKA or MAZE?
Oruka Therapeutics, Inc. has a quarterly dividend of $19.36 per share corresponding to a yield of 0%. Maze Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oruka Therapeutics, Inc. pays -- of its earnings as a dividend. Maze Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORKA or MAZE?
Oruka Therapeutics, Inc. quarterly revenues are --, which are smaller than Maze Therapeutics, Inc. quarterly revenues of --. Oruka Therapeutics, Inc.'s net income of -$30.3M is lower than Maze Therapeutics, Inc.'s net income of -$30.1M. Notably, Oruka Therapeutics, Inc.'s price-to-earnings ratio is -- while Maze Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oruka Therapeutics, Inc. is -- versus 501.13x for Maze Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORKAOruka Therapeutics, Inc.-- -- -- -$30.3M MAZEMaze Therapeutics, Inc.501.13x -- -- -$30.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
